<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, May 21, 2019 (HealthDay News) — Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at the American Thoracic Society 2019 International Conference, held from May 17 to 22 in Dallas.<\/p>\n
Nicola Alexander Hanania, M.D., from the Baylor College of Medicine in Houston, and colleagues examined the efficacy of dupilumab in patients with late-onset asthma and with baseline postbronchodilator forced expiratory volume in one second\/forced vital capacity (FEV1<\/sub>\/FVC) ratio <0.7 (indicating fixed airway obstruction) or \u22650.7 in a post hoc analysis of data from the phase 3 LIBERTY ASTHMA QUEST study.<\/p>\n The researchers found that compared with placebo, dupilumab 200 mg and 300 mg every two weeks significantly reduced the annualized rate of severe exacerbations in patients with late-onset asthma and fixed airway obstruction (\u221268.8 and \u221275.7 percent, respectively) and in patients without fixed airway obstruction (\u221255.1 and \u221250.7 percent, respectively). Pre- and postbronchodilator FEV1<\/sub> and FEV1<\/sub>\/FVC ratio improved in dupilumab-treated patients with late-onset asthma and fixed airway obstruction at week 12; similar improvements were seen at week 52. More modest improvements were seen for prebronchodilator FEV1<\/sub> at weeks 12 and 52 in late-onset asthma patients without fixed airway obstruction.<\/p>\n “Lung function improvements were observed at Weeks 12 and 52 in patients with late-onset asthma and fixed airway obstruction, who typically experience worse asthma outcomes than do those without fixed airway obstruction,” the authors write.<\/p>\n Several authors disclosed financial ties to Sanofi and Regeneron Pharmaceuticals, the manufacturers of dupilumab.<\/p>\n Abstract<\/a><\/p>\n